Gossamer Bio Inc (GOSS) Stock Analysis
Verdict: AVOID
Phase 3 seralutinib is the sole value driver, but a 2025 cash burn of $171M against $37M in liquidity makes a dilutive 'death spiral' likely.
Investment score: 38/100
Analysis as of
Is Gossamer Bio Inc stock worth reviewing? The TradeMates thesis
Avoid GOSS due to imminent insolvency risk and extreme cash burn that necessitates heavy dilution before Phase 3 data matures.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Gossamer Bio Inc opportunities and risks
What speaks for GOSS
- Phase 3 Seralutinib Potential
What speaks against GOSS
- Imminent Dilutive Financing/Insolvency
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| GOSS | n/a | 0.8x | n/a | 99.6% | -324.8% | -400.1% |
| KLRS | n/a | 0.0x | n/a | 0.0% | 0.0% | -60.8% |
| ALDX | n/a | 0.0x | n/a | 0.0% | 0.0% | -27.8% |
| PTHS | n/a | 0.6x | n/a | 47.0% | -186.2% | -204.3% |
| FBIO | 0.7x | 1.4x | n/a | 64.5% | 193.1% | 174.5% |
| BMEA | n/a | 0.0x | n/a | 0.0% | 0.0% | -63.3% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -60.8% |
Frequently asked questions about Gossamer Bio Inc (GOSS)
Is GOSS stock a good investment?
The TradeMates model rates Gossamer Bio Inc as AVOID with an investment score of 38/100. Avoid GOSS due to imminent insolvency risk and extreme cash burn that necessitates heavy dilution before Phase 3 data matures. This is algorithmic model output, not personal investment advice.
Is GOSS stock a buy?
The TradeMates model verdict for GOSS is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.